Phase 1 B-cell Malignancies Clinical Trials
16 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–16 of 16 trials
Recruiting
Phase 1
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+4 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.85 enrolled9 locationsNCT06980116
Recruiting
Phase 1
IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
Relapsed/Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology12 enrolled1 locationNCT07309900
Recruiting
Phase 1
The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
Relapsed/Refractory B-cell Malignancies
The First Affiliated Hospital with Nanjing Medical University30 enrolled6 locationsNCT07002112
Recruiting
Phase 1Phase 2
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
B-cell Malignancies
AstraZeneca174 enrolled30 locationsNCT06542250
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
B-cell Malignancies
Sheba Medical Center50 enrolled1 locationNCT07135466
Recruiting
Phase 1
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
Relapsed/Refractory B-cell Malignancies
Ubix Therapeutics, Inc.94 enrolled11 locationsNCT06590961
Recruiting
Phase 1
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Relapsed/Refractory B-cell Malignancies
Accutar Biotechnology Inc60 enrolled9 locationsNCT05780034
Recruiting
Phase 1Phase 2
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
B-cell Malignancies
Shenzhen Geno-Immune Medical Institute200 enrolled2 locationsNCT03050190
Recruiting
Phase 1Phase 2
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
B-cell Malignancies
Shenzhen Geno-Immune Medical Institute100 enrolled4 locationsNCT03125577
Recruiting
Phase 1
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies
Mature B-cell Malignancies
InnoCare Pharma Inc.78 enrolled8 locationsNCT06351527
Recruiting
Phase 1
Evaluation of SYS6005 in Patients With Advanced Malignant Tumor
Solid TumorsB-cell Malignancies
CSPC Megalith Biopharmaceutical Co.,Ltd.132 enrolled1 locationNCT06958679
Recruiting
Phase 1
A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
B-cell Malignancies
TransThera Sciences (Nanjing), Inc.37 enrolled1 locationNCT05683717
Recruiting
Phase 1
4SCAR19U T Cells Targeting B Cell Malignancies
B-cell Malignancies
Shenzhen Geno-Immune Medical Institute30 enrolled1 locationNCT05995015
Recruiting
Phase 1Phase 2
CD19/70 Bi-specific CAR-T Cell Therapy
B-cell Malignancies
Shenzhen Geno-Immune Medical Institute30 enrolled1 locationNCT05436496
Recruiting
Phase 1Phase 2
CD19/79b Bi-specific CAR-T Cell Therapy
B-cell Malignancies
Shenzhen Geno-Immune Medical Institute60 enrolled1 locationNCT05436509
Recruiting
Phase 1Phase 2
CD19/22 Bi-specific CAR-T Cell Therapy
B-cell Malignancies
Shenzhen Geno-Immune Medical Institute60 enrolled1 locationNCT05432882